| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study LB Saltz, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ... Journal of clinical oncology 26 (12), 2013-2019, 2008 | 2885 | 2008 |
| Platinum-based chemotherapy plus cetuximab in head and neck cancer JB Vermorken, R Mesia, F Rivera, E Remenar, A Kawecki, S Rottey, ... New England Journal of Medicine 359 (11), 1116-1127, 2008 | 2528 | 2008 |
| Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis GM Ruiz-Palacios, I Pérez-Schael, FR Velázquez, H Abate, T Breuer, ... New England Journal of Medicine 354 (1), 11-22, 2006 | 1962 | 2006 |
| Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial T André, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, A Bonetti, ... J clin oncol 27 (19), 3109-3116, 2009 | 1832 | 2009 |
| Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer JY Douillard, KS Oliner, S Siena, J Tabernero, R Burkes, M Barugel, ... New England Journal of Medicine 369 (11), 1023-1034, 2013 | 1665 | 2013 |
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with … JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ... Journal of clinical oncology 28 (31), 4697-4705, 2010 | 1630 | 2010 |
| OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch, M Buyse, ... Journal of clinical oncology 24 (3), 394-400, 2006 | 861 | 2006 |
| Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ... Journal of clinical oncology 26 (12), 2006-2012, 2008 | 847 | 2008 |
| Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study E Van Cutsem, F Rivera, S Berry, A Kretzschmar, M Michael, ... Annals of Oncology 20 (11), 1842-1847, 2009 | 578 | 2009 |
| PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with … LS Schwartzberg, F Rivera, M Karthaus, G Fasola, JL Canon, JR Hecht, ... Journal of clinical oncology 32 (21), 2240-2247, 2014 | 560 | 2014 |
| Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ... The lancet oncology 13 (12), 1225-1233, 2012 | 419 | 2012 |
| Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a … AC Linhares, FR Velázquez, I Pérez-Schael, X Sáez-Llorens, H Abate, ... The Lancet 371 (9619), 1181-1189, 2008 | 395 | 2008 |
| Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ... Annals of Oncology 25 (7), 1346-1355, 2014 | 315 | 2014 |
| Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final … E Díaz-Rubio, J Tabernero, A Gómez-Espana, B Massutí, J Sastre, ... Journal of Clinical Oncology 25 (27), 4224-4230, 2007 | 306 | 2007 |
| Mutations in BRIP1 confer high risk of ovarian cancer T Rafnar, DF Gudbjartsson, P Sulem, A Jonasdottir, A Sigurdsson, ... Nature genetics 43 (11), 1104, 2011 | 285 | 2011 |
| A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer M Ychou, W Hohenberger, S Thezenas, M Navarro, J Maurel, ... Annals of oncology 20 (12), 1964-1970, 2009 | 241 | 2009 |
| A germline variant in the TP53 polyadenylation signal confers cancer susceptibility SN Stacey, P Sulem, A Jonasdottir, G Masson, J Gudmundsson, ... Nature genetics 43 (11), 1098, 2011 | 211 | 2011 |
| From automatic antigay prejudice to behavior: The moderating role of conscious beliefs about gender and behavioral control. N Dasgupta, LM Rivera Journal of personality and social psychology 91 (2), 268, 2006 | 208 | 2006 |
| First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase … E Díaz-Rubio, A Gómez-España, B Massutí, J Sastre, A Abad, ... The oncologist 17 (1), 15-25, 2012 | 201 | 2012 |
| Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of … L Licitra, R Mesia, F Rivera, E Remenar, R Hitt, J Erfan, S Rottey, ... Annals of Oncology 22 (5), 1078-1087, 2010 | 196 | 2010 |
